Abstract
Atomoxetine is used commonly treatment of attention deficit hyperactivity disorder in children, adolescents, and adults. A validated GC–MS assay for the quantitation of atomoxetine in human plasma is presented in the study. The assay method is the first GC–MS-based method reported for the analysis of atomoxetine in plasma for therapeutic drug monitoring. The method has rapid analysis time and simple sample preparation. Atomoxetine and internal standard (IS) pseudoephedrine were extracted from plasma using a liquid-liquid extraction method. The assay method was validated according to the European Medicines Agency (EMA) Guideline on bioanalytical method validation. The lower limit of quantitation of the developed method was 200 ng/mL for atomoxetine. The calibration curve of atomoxetine was between 200 and 2000 ng/mL with showing correlation coefficients >0.99. Also, the method was applied to real patient’s plasma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
